Briakinumab for Treatment of Crohn's Disease: Results of a Randomized Trial

BACKGROUND: This study assessed the efficacy and safety of briakinumab, a human anti-IL-12/23p40 monoclonal antibody, compared with placebo for the induction and maintenance of remission in patients with moderately to severely active Crohn's disease. METHODS: In this phase 2b, multicenter, doub...

Descripción completa

Detalles Bibliográficos
Autores principales: Panaccione, Remo, Sandborn, William J., Gordon, Glenn L., Lee, Scott D., Safdi, Alan, Sedghi, Shahriar, Feagan, Brian G., Hanauer, Stephen, Reinisch, Walter, Valentine, John F., Huang, Bidan, Carcereri, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Original Clinical Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450894/
https://www.ncbi.nlm.nih.gov/pubmed/25989338
http://dx.doi.org/10.1097/MIB.0000000000000366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450894/
https://www.ncbi.nlm.nih.gov/pubmed/25989338
http://dx.doi.org/10.1097/MIB.0000000000000366

Ejemplares similares